Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs ...
DURING the last two decades great progress has been made in the experimental study and theoretical interpretation of molecular spectra, which has thus become one of the most important means we have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback